Research programme: cytidine/uridine monophosphate kinase 2 inhibitors - Gossamer Bio
Latest Information Update: 29 Jun 2023
At a glance
- Originator Gossamer Bio
- Class Anti-inflammatories; Small molecules
- Mechanism of Action CMPK2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Inflammation